Problem 10 - Campbell Biology

Question

SCIENTIFIC INQUIRY 50 years ago, pregnant women who were prescribed thalidomide for morning sickness gave birth to children with birth defects. Thalidomide is a mixture of two enantiomers; one reduces morning sickness, but the other causes severe birth defects. Today, the FDA has approved this drug for non-pregnant individuals with Hansen's disease (leprosy) or newly diagnosed multiple myeloma, a blood and bone marrow cancer. The beneficial enantiomer can be synthesized and given to patients, but over time, both the beneficial and the harmful enantiomer can be detected in the body. Propose a possible explanation for the presence of the harmful enantiomer.

Step-by-Step Solution

Answer

Racemization causes the beneficial enantiomer to convert into the harmful enantiomer in the body.

Step 1: Understand Enantiomers

Enantiomers are molecules that are mirror images of each other. They usually have very similar physical and chemical properties but can have drastically different biological effects.

Step 2: Understand Thalidomide's Enantiomers

In the case of thalidomide, one enantiomer helps to reduce morning sickness, and the other enantiomer causes severe birth defects.

Step 3: Recognize the Problem

Despite administering only the beneficial enantiomer to patients, both enantiomers are found in the body over time.

Step 4: Identify a Possible Cause

Consider that enantiomers can sometimes convert into one another. This process is known as racemization.

Step 5: Explain Racemization

In this process, the beneficial enantiomer can spontaneously convert into the harmful enantiomer under physiological conditions present in the human body. This explains why both enantiomers are detected over time.

Key Concepts

Understanding Enantiomers

Enantiomers are special types of molecules that are non-superimposable mirror images of each other. Think of your left and right hands; they are mirror images but cannot perfectly overlap. Despite having almost identical physical and chemical properties, enantiomers can interact with biological systems in remarkably different ways. This is because biological systems, like enzymes and receptors, are also chiral and can distinguish between the two enantiomers. As a result, one enantiomer of a drug could be beneficial while the other could be harmful.

The Process of Racemization

Racemization is the process by which one enantiomer of a compound transforms into its mirror image over time. This is especially relevant in the case of thalidomide. Even if only the beneficial enantiomer is administered, it can convert into the harmful enantiomer inside the body. This transformation happens under physiological conditions, such as the pH levels and temperature in human tissues. Because of racemization, both enantiomers can be detected in the body, explaining why harmful effects can still occur despite careful administration.

Connection Between Thalidomide and Birth Defects

In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women to alleviate morning sickness. Unfortunately, the drug was a mixture of two enantiomers. While one enantiomer was effective against morning sickness, the other caused severe birth defects like limb deformities. The severe consequences were due to the harmful enantiomer interfering with the developing fetus, demonstrating the vital importance of understanding enantiomeric properties in pharmaceuticals.

Thalidomide and Hansen's Disease

Today, thalidomide is FDA-approved for treating non-pregnant individuals with Hansen's disease, also known as leprosy. Hansen's disease affects the skin, nerves, and respiratory tract. Thalidomide helps by reducing inflammation and modulating the immune response. Because it has immunomodulatory properties, it can be effective in managing the symptoms of this chronic condition. The drug's usage in non-pregnant individuals minimizes the risk of birth defects caused by its harmful enantiomer.

Multiple Myeloma Treatment with Thalidomide

Thalidomide is also used in treating multiple myeloma, a type of blood and bone marrow cancer. It helps inhibit the growth of cancer cells by affecting the blood flow to tumors (anti-angiogenesis). The drug's anti-inflammatory and immunomodulatory properties further aid in slowing cancer progression. However, careful monitoring is essential to balance its therapeutic benefits against potential adverse effects due to racemization. By ensuring that thalidomide is used appropriately and with caution, its life-saving properties can be maximized.